Dr. Zhang on the Impact of the LATITUDE Study in Prostate Cancer

Tian Zhang, MD
Published: Tuesday, Oct 03, 2017



Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Median progression-free survival and overall survival were both markedly improved with the addition of abiraterone acetate (Zytiga) to standard androgen-deprivation therapy (ADT) compared with ADT alone in patients with newly diagnosed, high-risk, metastatic prostate cancer.
SELECTED
LANGUAGE


Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Median progression-free survival and overall survival were both markedly improved with the addition of abiraterone acetate (Zytiga) to standard androgen-deprivation therapy (ADT) compared with ADT alone in patients with newly diagnosed, high-risk, metastatic prostate cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x